Business
Trading Update
Futura Medical PLC anticipates FY25 revenue of £1.7 million, exceeding previous guidance, with net cash standing at £3.4 million following a November 2025 fundraise. The company expects a US$2.5 million milestone payment from Haleon in H1 2026, contingent on a US patent for Eroxon, and anticipates a £0.3 million tax credit refund for FY2025. These combined resources are projected to provide a cash runway until December 2026, aligning with prior statements. A strategic review of the business is ongoing and expected to conclude in Q1 2026, with outcomes to be announced with the Full Year Results in mid-April 2026. Disclaimer*
About this update from Futura Medical Plc
[{"type":"text","content":"\n\n4 February 2026\nFutura Medical plc\n(\"Futura\", \"the Group\" or the \"Company\")\nTrading Update\n \n \nFutura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon® and that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, is pleased to provide an unaudited trading update for the year ended 31 December 2025 (FY25).\n \nThe Company now expects to deliver FY25 revenue of £1.7 million, ahead of previously guided management expectations*. Additionally, net cash at year end was £3.4 million following the successful £2.75 million fundraise in November 2025. As previously announced, under the Company's existing agreement with Haleon and subject to the granting of a U.S. patent for Eroxon, the Company expects to trigger a milestone payment from Haleon of US$2.5 million during H1 2026; in addition, the Company expects to receive a tax credit refund for FY2025 of approximately £0.3 million.\n \nThe Company's existing cash resources including the net proceeds of the fundraise in November 2025, combined with the expected tax credit refund for the 2025 financial year, the US patent milestone payment from Haleon and proceeds from ongoing sales of Eroxon, are expected to provide the Company with a cash runway to December 2026, which is in line with prior statements.\n \nAs previously announced, the Board is undertaking a strategic review of the business and its operations which is expected to conclude in Q1 2026. The outcomes of the review will be published in the Company's Full Year Results which are expected to be released mid-April 2026.\n \n*On 19th September 2025, the Company disclosed that it expected to deliver revenue between £1.3 million and £1.4 million for FY25\n \nThe information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014 as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019.\n \n \nContacts:\n\n\n\n\nFutura Medical plc\n \n \n\n\nAlex Duggan\nChief Executive Officer\nAngela Hildreth\nFinance Director and COO\n \n\n\[email protected]\n+44 (0)1483 685 670\nwww.futuramedical.com\n \n\n\n\n\nPanmure Liberum\nNominated Adviser\nand Broker\n\n\nEmma Earl...